Patents by Inventor Elena Sancho Suils

Elena Sancho Suils has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150289795
    Abstract: The invention relates to methods for predicting the risk of relapse of cancer patients as well as methods for providing personalized medicine to said patients based on the expression levels of different genes the expression of which is induced in response to TGF-beta stimulation. The invention also relates to kits for carrying out the diagnostic and predictive medicine methods.
    Type: Application
    Filed: November 12, 2013
    Publication date: October 15, 2015
    Inventors: Eduard Batlle Gómez, Elena Sancho Suils, David Rossell Ribera, Alexandre Calon, Elisa Espinet Hernández, Sergio Palomo Ponce
  • Publication number: 20140314662
    Abstract: The invention relates to methods for predicting the risk of relapse of cancer patients as well as methods for providing personalized medicine to said patients based on the expression levels of different genes the expression of which is induced in response to TGF-beta stimulation. The invention also relates to kits for carrying out the diagnostic and predictive medicine methods.
    Type: Application
    Filed: November 12, 2012
    Publication date: October 23, 2014
    Inventors: Eduard Batlle-Gomez, Elena Sancho Suils, David Rossell Ribera, Alexandre Calon, Elisa Espinet Hernandez, Sergio Palomo Ponce
  • Publication number: 20040058392
    Abstract: The invention relates to the use of the expression products of the TCF target genes as markers for the isolation of intestinal stem cells in a method for the isolation of intestinal stem cells by providing antibodies, antibody derivatives or ligand fusion proteins against one or more of the target gene products of the genes; providing single cell suspensions of intestinal tissue; contacting the antibodies, antibody derivatives or ligand fusion proteins and the single cell suspensions; identifying the cells binding to the antibodies, antibody derivatives or ligand fusion proteins; and optionally isolating the stem cells from the antibodies, antibody derivatives or ligand fusion proteins.
    Type: Application
    Filed: September 17, 2002
    Publication date: March 25, 2004
    Applicant: Kylix B.V.
    Inventors: Johannes Carolus Clevers, Eduard Batlle Gomez, Marcus Lambertus Van De Wetering, Elena Sancho Suils
  • Publication number: 20040005313
    Abstract: The present invention relates to the use of inhibitors of the expressed proteins of TCF target genes whose expression is regulated by TCF/&bgr;-catenin complexes for the preparation of a therapeutical composition for the treatment of cancers in which TCF/&bgr;-catenin signaling is deregulated. Such inhibitors can be antibodies, small molecules, antisense RNA and dsRNA for use in RNAi. The invention also relates to these inhibitors per se.
    Type: Application
    Filed: July 16, 2002
    Publication date: January 8, 2004
    Applicant: Kylix B.V.
    Inventors: Johannes Carolus Clevers, Eduard Batle Gomez, Marcus Lambertus Van De Wetering, Elena Sancho Suils